首页/数据集/Co-administered medication and MMSE slope differences before and 6 months after AChEI initiation.

Co-administered medication and MMSE slope differences before and 6 months after AChEI initiation.

Figshare2015-12-02 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/_Co_administered_medication_and_MMSE_slope_differences_before_and_6_months_after_AChEI_initiation_/1247996 数据链接链接失效反馈

官方服务：

资源简介：

Co-administered medication and MMSE slope differences before and 6 months after AChEI initiation.

应用场景：

创建时间：

2015-12-02

阿尔茨海默病药物

临床试验代表性评估

Objective To determine whether there are differences in age and sex distribution and presence of comorbidities between participants included in randomized controlled trials of acetylcholinesterase inh

NIAID Data Ecosystem80

Data_Sheet_3_Cognition and Brain Activation in Response to Various Doses of Caffeine: A Near-Infrared Spectroscopy Study.XLSX

咖啡因神经效应

认知功能评估

Caffeine, which is widely used for enhancing athletic performance, has been suggested to have a positive impact on cognition via stimulating the brain. However, no study published to date has explored

NIAID Data Ecosystem40

Table 1_Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis.docx

痴呆症药物疗效比较

认知功能评估

BackgroundOver 44 million people worldwide live with dementia, affecting their quality of life and well-being. Choline alphoscerate and citicoline supplements are commonly used to improve cognitive fu

NIAID Data Ecosystem00

Discovery of Potent and Centrally Active 6‑Substituted 5‑Fluoro-1,3-dihydro-oxazine β‑Secretase (BACE1) Inhibitors via Active Conformation Stabilization

阿尔茨海默病药物

BACE1抑制剂设计

β-Secretase (BACE1) has an essential role in the production of amyloid β peptides that accumulate in patients with Alzheimer’s disease (AD). Thus, inhibition of BACE1 is considered to be a disease-mod

NIAID Data Ecosystem50

Additional file 1 of Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

阿尔茨海默病临床试验

认知功能评估

Additional file 1: Dataset S1. Collection of samples of CMA and placebo groups and the measured values of clinical indicators before and after treatment.

NIAID Data Ecosystem00

Co-administered medication and MMSE slope differences before and 6 months after AChEI initiation.

资源简介：

相关数据集